Browse by category

Novo Nordisk has announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorisation of Wegovy 7.2 mg (once-weekly injectable semaglutide 7.2 mg) in a single-dose pen and Wegovy pill. Wegovy 7.2 mg is already available in the EU for adults with obesity, dosed as three injections of 2.4 mg, and is based on results from the STEP UP trial programme. In the STEP UP